The big players are pumping hundreds of millions into Type one treatments and devices. Once LCT has confirmed results the US pharmas will all be circling for a piece of LCT, personally I believe that J&J will be the bidder once the results are out. Some snippits from today's papers show the interest and value this market offers:
"Medtronic's diabetes revenue jumped 18 percent in fiscal 2008, to just over $1.09 billion, helping to offset slowing sales in the company's core heart rhythm device business.
The diabetes business is focused on a number of technology advances, including an insulin pump that can automatically shut off insulin delivery if it detects blood sugar has fallen too low, a particular danger when a patient is sleeping. A pump with that safety feature is expected to gain approval for sale in Europe later this calendar year, O'Connell said. Both Insulet and J&J are working with DexCom to produce integrated systems that are expected to hit the market next year."
- Forums
- ASX - By Stock
- hmmmm. support broken
The big players are pumping hundreds of millions into Type one...
Add 1AI (ASX) to my watchlist
|
|||||
Last
0.9¢ |
Change
0.001(12.5%) |
Mkt cap ! $15.18M |
Open | High | Low | Value | Volume |
0.8¢ | 0.9¢ | 0.8¢ | $9.66K | 1.206M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 313539 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1373312 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 313539 | 0.008 |
14 | 5071214 | 0.007 |
11 | 4776749 | 0.006 |
6 | 2510009 | 0.005 |
4 | 4065000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1373312 | 9 |
0.010 | 3949819 | 10 |
0.011 | 1490400 | 3 |
0.012 | 816363 | 4 |
0.013 | 41918 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
1AI (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online